Celltrion achieves export declaration record of KRW 600 billion with Remsima

The last year’s export declaration record of ‘Remsima(rheumatoid arthritis treatment),’ a Celltrion’s biosimilar, was observed to be KRW 600 billion increased by approximately 5 times higher than the record of the year before.

The Remsima’s export declaration record of 2015 was aggregated at USD 492.639 million(approximately KRW 595.1 billion). It is a figure 4.8 times higher than the record o...